Research
Hormonal
Novel therapies, including dual and triple incretin agonists, are under investigation for obesity treatment.
Practitioners should stay informed about emerging therapies that may enhance obesity treatment.
StrongSupportsmedium confidence
Additionally, novel therapies, including dual and triple incretin agonists, are under investigation and hold the potential for further advancements in obesity treatment.
Why this rating
The abstract discusses ongoing investigations into these novel therapies.
Source
Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management
Ibrahim S. Alhomoud et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2024
reviewCited 19×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →